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Leech.derived antistasin s a potent anticoagulant and antimetastatie protein that binds ulfatide (Gal(3-SO4),~l-ICer) and sulfated polysaccharides. 
In this study, the synthetic fragment [A TM]  antistasin 93-119, which corresponds to the carboxyl terminus, showed ~pecifi¢ and saturable 
binding to sulfatide. Binding was competitively blocked by glycosaminoglyeans (GAGs) in the order: dextran sulfate 5000 ~, dextran sulfate 500 000 
> heparin> dermatan sulfate >> chondroitin sulfates A and C. This rank order of inhibitory potency was identical to that obmrvgd with whole 
antistasin. We suggest that residues 93-119 of antistasin represent a critical domain for binding GAGs and sulfated glycolipids. 
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1. INTRODUCTION 
Antistasin is a 119-amino acid leech protein from 
llaementer/a officinalis [1]. This protein, and a similar 
one from Haementeria ghilianii [2], inhibit the blood 
clotting enzyme Factor Xa. These inhibitors contain a 
2-fold internal repeated homology [3,4]. The amino- 
temainal domain contains the inhibitory residues that 
block the catalytic site of Factor Xa [3,4]. The carboxyl- 
terminal half contains a basic amino acid-rich tail that 
fits a consensus motif for binding glyeosamino- 
glycans(GAGs) [5]. At present, the domain(s) that 
mediates the specific interactions of antistasin with 
GAGs and sulfated glycolipids remains to be deter- 
mined. In this study,we demonstrate that [A ~°~'~°o'~ns] 
antistasin 93-119 mimics the interaction of whole anti- 
stasin with sulfatide and sulfated polysaccharides. 
2. EXPERIMENTAL 
[A t°~,t°~'~°K] antistasin 93-119 was synthesized as recently described 
[6] in which alanine for cysteine substitutions were made at positions 
103, 106 and 108 in order to prevent covalent aggregation during 
purification. Peptides purity was established by analytical high per- 
formance liquid chromatography, quantitative amino acid analysis [7] 
and fast atom bombardment mass spectrometry. Antistasin was 
purified from fresh salivary ~lands from Ha,,menteria officinalis as 
described in [1] and parity was established as described in [2]. Antista- 
~in and [A l°~'t~a°n] ant istasin 93-119 (50/~g) w~re radloiodinated with 
Na[ ~I] (17 Ci/mmol, Amersham-Searle, Arlington Heights, IL) using 
Corr¢alJondet~c¢ address; A.D. Cardin, Marion Mcrrelt Dow Research 
Institute, 2110 East Galbraith Rd., Cincinnati, OH 45215, USA. Fax: 
(1) (513) 948 6204. 
the chloramine-T method [8]. The reaction mixture was dgsaltgd on 
a Bin Gel P-2 column equilibrated in phosphate buffered saline, pH 
7.4 (PBS); 0.5 mi fractions were collected in teflon coated tubes con- 
taining 1120/~1 of PBS and 6 mg/ml BSA. Th~ labeled samples were 
stored at -80°C and a fresh tube thawed for each experiment. 
The well., of lmmulon 4 Rcmovaw¢ll polystyrene microtitre plates 
(Dynatech laboratories, Inc., Chantilly, VA) were coated with 200/~1 
of 1120/Jg/ml Gal(3-SO4)~l-Cer (sulfatide; Sigma, St. Louis, MO) in 
methanol. The solvent was evaporated with nitrogen and the plate 
subjected to high vacuum for 20--30 min. Wells were blocked for 2 h 
with 250/~1 ,:ff 1% bovine serum albumin (BSA) in standard buffer (10 
mM HEPE!;', 0.15 M NaCI, pH 7.4), aspirated and washed Zl-times. 
Next, inere:~ing amounts of ~ZSl-labeled antistasin or t-~al-labeled 
[A j°~,~°~'j°~] aatistasin 93-119 were added. After 3--4 h at room temper- 
ature the we;ls were aspirated and washed as above, tzSI-labeled anti- 
stasin and t v l-labeled [A ~°~'~°~'~] antistasin 93-119 bound to sulfatide 
were then determined by gamma counting. For competition studies, 
increasing amounts of GAGs were added, followed by a constant 
amount of ~-'~l-labcled [A~°~'~'L°a] antistasln 93-119 or ~25I-labeled 
antistasin. The wells were incubated and washed as described above 
until the cot~nts in the wash were near to background. The amount of 
peptidc bound to sulfatide was determined by gamma counting. 
Heparin I.~inding was zsses~l by adding increasing amounts of 
l'~I-lab~led tA~°~'t°~'~°"l antistasin 93-119 to Eppendorf tubes contain- 
ing 100/zl of heparin agarose (Bethesda Researseh Laboratories Life 
Technologies Inc., Oaither~burg, MD) in a final volume of 250/~1 of 
50 mM HEPES, 0.1 M NaCl, pH 7.4. The tubes were incubated for 
5 min at room temperature, centrifuged and counts in the supgrnatant 
w~re determined. 
3. RESULTS AND DISCUSSION 
Fig. i shows that the binding of t-'~l-labeled 
[A ~n3,1°~.l°s] antistasin 93-119 to GaI(3-SO4)]~I-I Cer was 
saturable and specific as negligible binding occurred in 
the absence of sulfatide. As shown, this l~ptide contains 
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Fig. 1. The binding of "~l-labeled [A ~°'~'~c~'l°~] antistasin 93-119 to 
sulfatid¢, Microtiter wells were coated (11) or not coated (O) with 
sulfatide. 
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Fig. 3. The eff~t of various glyeosaminoglycans o  the binding of 
[A ~°~'~°~'~°~1 antistasin 93-119 to Oal(3-SO4)fll.Cer. Dextran sulfate 
5000 (q,); deatran sulfate 500 000 (&); heparin (e); dermatan sulfate 
f~); chondroitin sulfates A (8) and C (©). 
2 basic-rich amino acid regions (underlined) that paten. 
tially mediate antistasin°s interaction with sulfated gly- 
colipids and GAGs. Radioiodination occurred at Tyr- 
105, 3 and 4 residues removed from these domains. 
Fig. 2 shows that the binding of L2SI-labeled 
[A m3't°~'m~] antistasin 93-119 to heparin agaroso was 
specific for the GAG as unlabeled heparin caused its 
release into the supernatant. Thus, Figs. 1 and 2 demon- 
strate that [A la3'l°6'mg] antistasin 93-119 binds both to 
sulfatide and heparin. As GAGs are known to block the 
antistasin-sulfatide nteraction [9] the relative ability of 
various ulfated polysaccharides to block the binding of 
tAm3.106, m,] antistasin 93-119 to Ga1(3-SO4)~61-1 Cer was 
examined. The results of a representative experiment 
are shown in Fig. 3 and the data from 4 such exper- 
iments are summarized in Table I. The relative order of 
the inhibitory potencies (dextran sulfate 5000 = dextran 
sulfate 500000 > heparin > dermatan sulfate :~ chon- 
droitin sulfates A and C) and their ratios (dextran 
sulfate: heparin and dextran sulfate: dermatan sulfate) 
were nearly identical to those reported to block the 
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Fig, 2. The binding of ~ZSl-labeled [A I°~'t°~'l°~] antistasin 93-119 to 
heparin agarose in the absence (m) and presence (e) of 10 mg/ml 
heparin. 
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binding of antistasin to sulfatide [9] and ~-51-1abeled 
heparin binding to [A t°~'l°6'l°~] antistasin 93-119 [6]. 
Thus antistasin and its carboxyl-terminal t il (residues 
93-119) show the same quantitative relationships be- 
tween their GAG and sulfatide binding properties. The 
relative abilities of dextran sulfate, heparin and der- 
matan sulfate to suppress the binding of antistasin to 
sulfatide are shown in Fig. 4. Dextran sulfate and hepa- 
rin were considerably more potent than dermatan 
sulfate, whilst chondroitin sulfates A and C (not shown) 
were inactive at all concentrations tested. 
In summary, this study demonstrates that residues 
93-119 of antistasin mimics the interaction of antistasin 
with sulfatide and sulfated polysaccharides. Site- 
directed mutational studies should clarify further the 
functional role of this domain in the in viva anticoag- 
Table 1 
Effect of sulfated polysaccharides on the bindln 8 of t-%l-labeled 
[A l°3,t°~'l°n] antistasin 93-119 to sulfatide 
GAG ICso (t,u~/ml) ~ 
Peptide'/ Heparin"/ 
salfatide b p0ptide" 
Heparin 90 (16) (100) 
Dextran sulfate 5000 8 (1.4) (7) 
De~tran sulfate 500 000 9 (1.5) (8) 
Dermatan sulfate 950 (195) (1000) 
Chondroitin sulfate A >1000 (>500) (>1000) 
Chondroitin sulfate C > 1000 (>500) (> 1000) 
" Concentration of GAG giving 50% inhibition of binding. 
b Values in parentheses reported by Holt ol al. [9] for whole antistasin 
binding to sulfatide. 
= Data in parentheses are those of Manley et al, [61. 
• Indicates radioiodinated [A ~°3,~°~'t6s] antistasin 93-I19 bound to 
Gal(3-SO4)pl-lCer that is displaced by the various GAGs. 
"Indicates radioiodinated heparin bound to [A ~°~'l°~'~°"] antistasin 93- 
119 that is displaced by the various GAGs, 
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Fig. 4. The effect of various glycosaminoglycans o  the binding of 
LaSl.labeled whole antistasin to sulfatid¢, Solid bar, control (no eom- 
petltor added); striped bar, dextran sulfate 5000; cross-hatched bar, 
heparin; open bar, dermatan sulfate. No inhibition was observed with 
chondroitin sulfates A and C at 1 mg/ml. 
ulant,  ant imetastat ie  and pharmacok inet i¢  behav iour  o f  
the inhibitor ,  
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